Overview

• Kathryn Oddie, 63, was diagnosed with multiple myeloma in 2000 after a sudden nosebleed and given a five-year prognosis.
• Over two decades, she underwent 11 lines of therapy, including two stem cell transplants and numerous clinical trials, before exhausting treatment options in 2020.
• In January 2021, she enrolled in a trial for teclistamab, a novel immunotherapy, achieving remission for the first time within six months.
• Now in remission and on a reduced dose of teclistamab, Oddie is focusing on family life with her grandchildren and advocating for continued research into blood cancer treatments.
• Her journey highlights the challenges of diagnosing myeloma, the transformative impact of experimental drugs, and the need for expanded treatment options.